Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobemstomig ± Tiragolumab Versus Atezolizumab in First-Line Platinum-Ineligible Metastatic Urothelial Cancer
2023-504027-78-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jan 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of tobemstomig in urothelial carcinoma (UC) (3 arms), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Planned start Jan 2023; status: authorised.
02
Drugs
tobemstomig
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on 2023-504027-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504027-78-00.